Insider Buying: Stereotaxis (NYSEAMERICAN:STXS) Director Acquires $44,800.00 in Stock

Stereotaxis Inc. (NYSEAMERICAN:STXS) Director Paul Isaac bought 20,000 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were bought at an average price of $2.24 per share, with a total value of $44,800.00. Following the completion of the purchase, the director owned 2,786,557 shares in the company, valued at approximately $6,241,887.68. The trade was a 0.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Stereotaxis Price Performance

Shares of NYSEAMERICAN STXS traded up $0.17 during trading hours on Tuesday, reaching $2.29. The stock had a trading volume of 694,472 shares, compared to its average volume of 477,972. The company has a market cap of $208.09 million, a price-to-earnings ratio of -7.88 and a beta of 1.65. Stereotaxis Inc. has a twelve month low of $1.54 and a twelve month high of $3.59. The business’s fifty day moving average is $2.92 and its two-hundred day moving average is $2.54.

Hedge Funds Weigh In On Stereotaxis

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in Stereotaxis by 106.5% in the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after buying an additional 5,910 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Stereotaxis in the first quarter valued at approximately $37,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Stereotaxis in the 3rd quarter worth approximately $38,000. Moneta Group Investment Advisors LLC acquired a new position in shares of Stereotaxis in the 3rd quarter worth approximately $43,000. Finally, Boothbay Fund Management LLC bought a new stake in Stereotaxis during the 3rd quarter worth approximately $54,000. 45.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Roth Capital reaffirmed a “buy” rating and set a $4.00 price objective on shares of Stereotaxis in a report on Wednesday, November 12th. UBS Group set a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 5th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $4.00.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.